Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb Signs Merger Agreement With Medarex
Bristol-Myers Squibb and Medarex have signed a merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16 per share in cash. Bristol-Myers Squibb will pay
Bristol-Myers Squibb and Medarex have signed a merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16 per share in cash. Bristol-Myers Squibb will pay
Response Genetics has entered into a purchase agreement with certain funds managed by Lansdowne Partners Limited Partnership, to raise approximately $4 million. The company is likely to raise
Peregrine and Affitech have entered into a licensing agreement for antibody therapeutic rights, under the Peregrine’s preclinical anti-VEGF (Vascular Endothelial Growth Factor) antibody program. As per terms of
Human Genome Sciences has reported that the net loss for the second quarter ended June 30, 2009, decreased to $65.4 million or $0.48 per share, compared to a
OSI Pharmaceuticals has reported total revenues from continuing operations of $99 million for the second quarter of 2009, as compared to revenues of $96 million for the second
Alcon has entered into a five-year collaborative research agreement with AstraZeneca, for the exclusive ophthalmic discovery and potential development rights to AstraZeneca’s compound library. Reportedly, the two companies
Cellceutix has completed acute toxicity studies in mice and rats with its Kevetrin. In these studies, Kevetrin showed no significant indications of toxicity. In the acute toxicity mouse
FDA has extended the review of Takeda’s New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS (pioglitazone HCl). Reportedly, the NDA for the FDC
Alexion Pharmaceuticals, engaged in the discovery, development and commercialization of therapeutic products, has reported a 55% increase in revenue for its second quarter ended June 30, 2009. The
Anika Therapeutics has reported that total revenue for the second quarter of 2009 showed an increase of 5%, to $9.52 million, from $9.06 million in the second quarter